CELL INTELLIGENCE · 肿瘤细胞治疗研究

自体 CD5-KO 抗 CD5 CAR-T 细胞在复发/难治性 CD5⁺ 血液系统恶性肿瘤中的疗效与安全性

Efficacy and safety of autologous CD5-KO anti-CD5 CAR-T cells in relapsed/refractory CD5(+) hematological malignancies.

CAR-T 细胞：改善儿童肿瘤结局所缺失的一环？

CAR T cells: the missing piece needed to improve outcomes for children with cancer?

单细胞解析揭示 CD5 或 CD7 靶向 CAR-T 细胞治疗后的免疫失调

Single-Cell Dissection Reveals Immune Dysregulation After CD5 or CD7-Directed Chimeric Antigen Receptor T-Cell Therapy.

通过光学与 PSMA 靶向 PET 成像开发原位 CAR-T 细胞方案

Development of an in situ CAR-T cell protocol through optical and PSMA-targeted PET imaging.

微流控细胞转染装置整合至基因编辑 CAR-T 细胞生产流程的开发

Development of a microfluidic cell transfection device into gene-edited CAR T cell manufacturing workflow.

免疫治疗在成人急性白血病治疗中处于何种地位？

Where do immunotherapies stand in management of acute leukemia in adults?

CD5 表达对复发/难治性弥漫大 B 细胞淋巴瘤 CAR-T 细胞治疗结局的影响

Impact of CD5 expression on outcomes for chimeric antigen receptor-T cell therapy in relapsed and refractory diffuse large B-cell lymphoma.

慢性淋巴细胞白血病/小淋巴细胞淋巴瘤中微小/可测量病灶的流式细胞术分析

Minimal/Measurable Disease Analysis in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma by Flow Cytometry.

Epcoritamab 在 CAR-T 治疗后复发 CD19-CD5+ 弥漫大 B 细胞淋巴瘤中的有效且安全给药

The effective and safe administration of Epcoritamab in relapsed CD19-CD5+ DLBCL following CAR-T therapy.

该病例凸显了 epcoritamab 联合减瘤治疗用于治疗 CAR-T 难治性 CD19 阴性 DLBCL 的潜力。

用于肿瘤免疫治疗的体外自体造血干细胞来源 T 淋巴细胞的生成

Generation of ex vivo autologous hematopoietic stem cell-derived T lymphocytes for cancer immunotherapy.